dareq
delorbis pharmaceuticals ltd. - desloratadine - tablets film-coated - 5mg
dareq 5 mg film-coated tablets
delorbis pharmaceuticals limited 17 athinon str, ergates industrial area, 2643 ergates, po box 28629, 2081 lefkosia, cyprus - film-coated tablet - desloratadine 5 mg - antihistamines for systemic use
gedarel extra 30/150 micrograms film coated tablets
gedeon richter plc - ethinylestradiol; desogestrel - film-coated tablet - 30mcg/150 microgram(s) - progestogens and estrogens, fixed combinations; desogestrel and ethinylestradiol
gedarel 20/150 microgram film-coated tablets
gedeon richter plc - ethinyloestradiol; desogestrel - film-coated tablet - 20mcg/150 microgram(s) - progestogens and estrogens, fixed combinations; desogestrel and ethinylestradiol
gedarel 20microgram/150microgram tablets
gedeon richter (uk) ltd - desogestrel; ethinylestradiol - oral tablet - 150microgram ; 20microgram
gedarel 30microgram/150microgram tablets
gedeon richter (uk) ltd - desogestrel; ethinylestradiol - oral tablet - 150microgram ; 30microgram
chlordiazepoxide hydrochloride capsule
aidarex pharmaceuticals llc - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr) - chlordiazepoxide hydrochloride 25 mg - chlordiazepoxide hcl capsules are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of chlordiazepoxide hcl capsules in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. chlordiazepoxide hcl capsules are contraindicated in patients with known hypersensitivity to the drug. chlordiazepoxide hydrochloride capsules are classified by the drug enforcement administration as a schedule iv controlled substance. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discon
metoclopramide tablet
aidarex pharmaceuticals llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets are indicated for the relief of sympt